Background: The recurrence of hepatitis C viral infection is common after liver transplant, and achieving a sustained virological response to antiviral treatment is desirable for reducing the risk of graft loss and improving patients' survival. Aim: To investigate the long-term maintenance of sustained virological response in liver transplant recipients with hepatitis C recurrence. Methods: 436 Liver transplant recipients (74.1% genotype 1) who underwent combined antiviral therapy for hepatitis C recurrence were retrospectively evaluated. Results: The overall sustained virological response rate was 40% (173/436 patients), and the mean follow-up after liver transplantation was 11. ±. 3.5 years (range, 5-24). Patients with a sustained virological response demonstrated a 5-year survival rate of 97% and a 10-year survival rate of 93%; all but 6 (3%) patients remained hepatitis C virus RNA-negative during follow-up. Genotype non-1 (p= 0.007), treatment duration >80% of the scheduled period (p= 0.027), and early virological response (p= 0.002), were associated with the maintenance of sustained virological response as indicated by univariate analysis. Early virological response was the only independent predictor of sustained virological response maintenance (p= 0.008). Conclusions: Sustained virological response achieved after combined antiviral treatment is maintained in liver transplant patients with recurrent hepatitis C and is associated with an excellent 5-year survival.
Long-term maintenance of sustained virological response in liver transplant recipients treated for recurrent hepatitis C / F.R. Ponziani, R. Viganò, R.M. Iemmolo, M.F. Donato, M. Rendina, P. Toniutto, L. Pasulo, M.C. Morelli, P. Burra, L. Miglioresi, M. Merli, D. Di Paolo, S. Fagiuoli, A. Gasbarrini, M. Pompili, L. Belli, G.E. Gerunda, M. Marino, R. Montalti, F. Di Benedetto, N. De Ruvo, C. Rigamonti, M. Colombo, G. Rossi, A. Di Leo, L. Lupo, V. Memeo, R. Bringiotti, M. Zappimbulso, D. Bitetto, V. Vero, M. Colpani, E. Fornasiere, A.D. Pinna, M.C. Morelli, V. Bertuzzo, E. De Martin, M. Senzolo, G.M. Ettorre, U. Visco-Comandini, G. Antonucci, M. Angelico, G. Tisone, V. Giannelli, M. Giusto. - In: DIGESTIVE AND LIVER DISEASE. - ISSN 1590-8658. - 46:5(2014), pp. 440-445. [10.1016/j.dld.2014.01.157]
Long-term maintenance of sustained virological response in liver transplant recipients treated for recurrent hepatitis C
M. Colombo;G. Rossi;
2014
Abstract
Background: The recurrence of hepatitis C viral infection is common after liver transplant, and achieving a sustained virological response to antiviral treatment is desirable for reducing the risk of graft loss and improving patients' survival. Aim: To investigate the long-term maintenance of sustained virological response in liver transplant recipients with hepatitis C recurrence. Methods: 436 Liver transplant recipients (74.1% genotype 1) who underwent combined antiviral therapy for hepatitis C recurrence were retrospectively evaluated. Results: The overall sustained virological response rate was 40% (173/436 patients), and the mean follow-up after liver transplantation was 11. ±. 3.5 years (range, 5-24). Patients with a sustained virological response demonstrated a 5-year survival rate of 97% and a 10-year survival rate of 93%; all but 6 (3%) patients remained hepatitis C virus RNA-negative during follow-up. Genotype non-1 (p= 0.007), treatment duration >80% of the scheduled period (p= 0.027), and early virological response (p= 0.002), were associated with the maintenance of sustained virological response as indicated by univariate analysis. Early virological response was the only independent predictor of sustained virological response maintenance (p= 0.008). Conclusions: Sustained virological response achieved after combined antiviral treatment is maintained in liver transplant patients with recurrent hepatitis C and is associated with an excellent 5-year survival.File | Dimensione | Formato | |
---|---|---|---|
10-Long-term maintenance of sustained virological response in liver transplant recipients treated for recurrent hepatitis C.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
521.35 kB
Formato
Adobe PDF
|
521.35 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.